BioNTech and Pfizer stated on Wednesday a 3-shot path in their COVID-19 vaccine became capable of neutralise the brand new Omicron variation in a laboratory
BioNTech and Pfizer stated on Wednesday a 3-shot path in their COVID-19 vaccine became capable of neutralise the brand new Omicron variation in a laboratory
